NSI-189
Also known as SNN-012
Investigational neurogenic small molecule often discussed in nootropic circles despite limited human data.
Evidence visual
NSI-189 evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
medium
Regulatory
investigational
WADA
none
FDA
unknown
Route
oral
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
NSI-189 is not a peptide but an investigational neurogenic compound included here because users often compare it with cognitive peptide stacks. Early human work suggests tolerability and possible mood or hippocampal effects, but the evidence base is still small and not sufficient for strong consumer conclusions.
Decision path
Where NSI-189 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether NSI-189 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Putative neurogenic and synaptogenic signaling; exact mechanism remains incompletely characterized.
oral
Early human studies used up to 40 mg daily by mouth.
Possible mood and cognitive-support effects remain speculative outside limited early human studies.
Any central effects would be expected over weeks rather than days.
No clear formal contraindications; treat as an experimental CNS-active compound.
Limited human safety base; mild insomnia or GI upset reported in small studies.
Avoid confident multi-nootropic stacking claims because mechanistic overlap and safety data are limited.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Two experimental neurotrophic-style agents with little human combination data.
Experimental nootropic stack with limited human data and unclear downside profile.
Mechanistically interesting but human combination data are weak; conservative caution.
CNS-active experimental pairing with uncertain interaction profile.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for NSI-189.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.